Stay updated on Lenvatinib+Pembrolizumab in Metastatic Gastroesophageal Cancer Clinical Trial

Sign up to get notified when there's something new on the Lenvatinib+Pembrolizumab in Metastatic Gastroesophageal Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lenvatinib+Pembrolizumab in Metastatic Gastroesophageal Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The study record area changes from a 403 Forbidden response to a “TypeError: Failed to fetch” message. The NIH transition notice is no longer displayed.
    Difference
    1%
    Check dated 2026-11-08T05:00:56.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-01T02:44:29.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A notice appears announcing NIH website updates and explaining that “Super Intelligence” may be used in place of “Artificial Intelligence” during the transition.
    Difference
    1%
    Check dated 2026-10-25T02:49:23.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T02:39:56.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer revision identifier changes from `v3.7.0` to `v3.7.1`; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T03:16:53.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    A 403 Forbidden page is now displayed in place of the study record, blocking access to the trial's details and attached documents. This prevents users from viewing core trial information such as the study description, eligibility, and related materials on the page.
    Difference
    15%
    Check dated 2026-09-20T01:29:50.000Z thumbnail image

Stay in the know with updates to Lenvatinib+Pembrolizumab in Metastatic Gastroesophageal Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lenvatinib+Pembrolizumab in Metastatic Gastroesophageal Cancer Clinical Trial page.